The new article describes the basics of international collaboration, aimed at further improvement of the regulatory framework and establishing a more efficient information exchange in order to ensure the proper performance of healthcare products as well as the safety of patients.
Table of content
The Drug Regulatory Authority of Pakistan (DRAP), a country’s agency in the sphere of healthcare products, has published a new revision of the guidelines on the national pharmacovigilance system. The document provides an overview of the applicable regulatory requirements, as well as additional clarifications and recommendations to be taken into consideration by medical device manufacturers and other parties involved in order to ensure compliance.
At the same time, the authority reserves the right to make changes to the document, should such changes be reasonably necessary to reflect corresponding amendments to the underlying legislation.
Overview of Pharmacovigilance Indicators
According to the guidance, pharmacovigilance indicators serve as essential tools to evaluate the effectiveness and efficiency of pharmacovigilance systems. These indicators measure inputs, processes, outputs, outcomes, and impacts of pharmacovigilance-related policies, projects, and activities within healthcare systems.
Their primary purpose is to assess the extent to which pharmacovigilance objectives, particularly patient safety, are being achieved. By identifying strengths, weaknesses, and areas requiring improvement, these indicators help ensure a robust pharmacovigilance framework.
Some indicators are assessed frequently, such as annually, while others – especially those requiring epidemiological studies or surveys – are evaluated less frequently due to the resource-intensive nature of such measurements.
Types of Pharmacovigilance Indicators
As further explained by the authority, the main types of pharmacovigilance indicators include:
- Structural Indicators. These indicators evaluate the presence of key pharmacovigilance infrastructure, systems, and mechanisms. They focus on qualitative measures like the existence of pharmacovigilance centres, policies, and statutory provisions, ensuring a foundation for pharmacovigilance activities. Examples include the presence of reporting forms, regulatory authorities, and dedicated budgets for pharmacovigilance operations.
- Process Indicators. Process indicators measure the extent and functionality of pharmacovigilance activities, such as the collection, collation, and analysis of adverse drug reaction (ADR) reports. These indicators assess how well pharmacovigilance systems operate and directly or indirectly reflect the efficiency of ongoing processes.
- Outcome or Impact Indicators. These indicators focus on the results of pharmacovigilance activities. They assess the system’s effectiveness in achieving its objectives, such as detecting signals, taking regulatory actions, and reducing medicine-related adverse events and hospitalizations.
Categories of Pharmacovigilance Indicators
The document also describes the main categories of pharmacovigilance indicators as set forth under the existing legal framework.
They include:
- Core Indicators. Core indicators are highly relevant for evaluating pharmacovigilance systems. They consist of 10 structural, 9 process, and 8 outcome indicators, encompassing critical areas like the existence of pharmacovigilance centres, ADR reporting rates, and regulatory actions taken based on pharmacovigilance data.
- Complementary Indicators. These indicators provide additional insights into the pharmacovigilance framework. While not mandatory, they enhance the understanding of pharmacovigilance performance. They include 11 structural, 13 process, and 12 outcome indicators, focusing on aspects like web-based training tools, healthcare facility involvement, and the impact of pharmacovigilance on health budgets.
- Indicators for Public Health Programmes. Specific indicators are designed for pharmacovigilance in public health programmes. These address the unique challenges and objectives of monitoring medicines and interventions in public health settings.
Core Pharmacovigilance Indicators: Examples
In order to assist the parties involved with understanding the concepts described above, the authority also provides a few examples:
- Structural Indicators include the existence of a pharmacovigilance centre with proper infrastructure, statutory budgets, and standardized reporting forms that cover ADRs, therapeutic ineffectiveness, and medication errors. They also assess the integration of pharmacovigilance into healthcare education and the availability of advisory committees.
- Process Indicators measure activities like the number of ADR reports received annually, causality assessments conducted, and the extent of active surveillance. For example, one indicator tracks the percentage of pharmaceutical companies with functional pharmacovigilance systems.
- Outcome Indicators assess the tangible results of pharmacovigilance activities, such as the number of signals detected, regulatory actions taken, and reductions in medicine-related hospitalizations and deaths. They also calculate the cost impact of pharmacovigilance on healthcare systems.
Complementary Pharmacovigilance Indicators: Highlights
Complementary structural indicators examine aspects like the availability of libraries for drug safety information and dedicated computers for pharmacovigilance. Process indicators focus on stakeholder participation in ADR reporting and pharmacovigilance training.
Outcome indicators delve deeper into the economic and social impacts of pharmacovigilance, such as cost savings and preventable ADRs.
Conclusion
In summary, pharmacovigilance indicators provide a comprehensive framework to monitor the development and effectiveness of pharmacovigilance systems. They not only facilitate continuous improvement but also support the optimization of healthcare systems by ensuring the safe use of medicines and minimizing risks to patients. These indicators enable policymakers and stakeholders to make informed decisions, thus promoting a culture of safety and accountability in pharmacovigilance practices.
How Can RegDesk Help?
RegDesk is an AI-powered Regulatory Information Management System that provides medical device companies with regulatory intelligence for over 120 markets worldwide. It can help you prepare and publish global applications, manage standards, run change assessments, and obtain real-time alerts on regulatory changes through a centralized platform. Global expansion has never been this simple.
